良性前列腺梗阻患者尿潴留的管理:系统评价与Meta分析
该系统评价与Meta分析检索截至2018年4月22日的文献,纳入21项研究,评估药物与非药物治疗良性前列腺梗阻所致尿潴留的证据。α1受体阻滞剂(阿夫唑嗪、坦索罗辛)可能提高成功拔管试验率,多数非药物治疗证据不足,结论不确定。
要点
- 阿夫唑嗪组成功拔管试验率60% vs 安慰剂组39%(OR 2.28,95%CI 1.55-3.36,低证据质量)。
- 坦索罗辛组成功拔管试验率47% vs 安慰剂组29%(OR 2.40,95%CI 1.29-4.45,低证据质量)。
- 坦索罗辛与阿夫唑嗪成功拔管试验率相似(59% vs 54%,OR 1.28,95%CI 0.68-2.41,极低证据质量)。
核心结论
- 有一些证据表明使用α1受体阻滞剂(阿夫唑嗪和坦索罗辛)可能改善良性前列腺梗阻所致尿潴留的缓解。
- 由于大多数非药物治疗未在良性前列腺梗阻所致尿潴留患者中评估,其获益与危害的证据尚不确定。
研究设计与样本
- 系统评价与Meta分析,检索CENTRAL、MEDLINE、Embase、ClinicalTrials.gov和世界卫生组织国际临床试验注册平台,截至2018年4月22日。
- 纳入随机对照试验(RCT)和前瞻性比较研究,遵循Cochrane手册方法,采用GRADE方法评估证据质量(CoE)。
- 文献检索识别2074条引文,最终纳入21项研究进行定性综合。
主要发现
- 阿夫唑嗪组成功拔管试验率322/540(60%) vs 安慰剂组156/400(39%),OR 2.28(95%CI 1.55-3.36;参与者=940;研究=7;I²=41%;低证据质量)。
- 坦索罗辛组成功拔管试验率75/158(47%) vs 安慰剂组40/139(29%),OR 2.40(95%CI 1.29-4.45;参与者=297;研究=3;I²=30%;低证据质量)。
- 坦索罗辛组与阿夫唑嗪组成功拔管试验率相似:51/87(59%) vs 45/84(54%),OR 1.28(95%CI 0.68-2.41;参与者=171;研究=2;I²=0%;极低证据质量)。
- α1受体阻滞剂不良事件罕见。
- 非药物治疗仅在RCT或前瞻性比较研究中间歇性评估。
关键数值与推荐
- 阿夫唑嗪组成功拔管试验率60% vs 安慰剂组39%(OR 2.28,95%CI 1.55-3.36;低证据质量)。
- 坦索罗辛组成功拔管试验率47% vs 安慰剂组29%(OR 2.40,95%CI 1.29-4.45;低证据质量)。
- 坦索罗辛组与阿夫唑嗪组成功拔管试验率59% vs 54%(OR 1.28,95%CI 0.68-2.41;极低证据质量)。
临床怎么用
- 原文结论指出,有一些证据表明使用α1受体阻滞剂(阿夫唑嗪和坦索罗辛)可能改善良性前列腺梗阻所致尿潴留的缓解。
- 原文结论指出,大多数非药物治疗未在良性前列腺梗阻所致尿潴留患者中评估,其获益与危害的证据尚不确定。
局限性
- 管理良性前列腺梗阻所致尿潴留的药物或非药物治疗证据有限。
- 大多数结局的证据质量低或极低。
- 仅α1受体阻滞剂(阿夫唑嗪和坦索罗辛)在超过一项RCT中评估。
- 非药物治疗仅在RCT或前瞻性比较研究中间歇性评估。
- 由于大多数非药物治疗未在良性前列腺梗阻所致尿潴留患者中评估,其获益与危害的证据尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Practice patterns for the management of urinary retention (UR) secondary to benign prostatic obstruction (BPO; UR/BPO) vary widely and remain unstandardized. OBJECTIVE: To review the evidence for managing patients with UR/BPO with pharmacological and nonpharmacological treatments included in the European Association of Urology guidelines on non-neurogenic male lower urinary tract symptoms. EVIDENCE ACQUISITION: Search was conducted up to April 22, 2018, using CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform. This systematic review included randomized controlled trials (RCTs) and prospective comparative studies. Methods as detailed in the Cochrane handbook were followed. Certainty of evidence (CoE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. EVIDENCE SYNTHESIS: Literature search identified 2074 citations. Twenty-one studies were included (qualitative synthesis). The evidence for managing patients with UR/BPO with pharmacological or nonpharmacological treatments is limited. CoE for most outcomes was low/very low. Only α1-blockers (alfuzosin and tamsulosin) have been evaluated in more than one RCT. Pooled results indicated that α1-blockers provided significantly higher rates of successful trial without catheter compared with placebo [alfuzosin: 322/540 (60%) vs 156/400 (39%) (odds ratio {OR} 2.28, 95% confidence interval {CI} 1.55 to 3.36; participants=940; studies=7; I2=41%; low CoE); tamsulosin: 75/158 (47%) vs 40/139 (29%) (OR 2.40, 95% CI 1.29 to 4.45; participants=297; studies=3; I2=30%; low CoE)] with rare adverse events. Similar rates were achieved with tamsulosin or alfuzosin [51/87 (59%) vs 45/84 (54%) (OR 1.28, 95% CI 0.68 to 2.41; participants=171; studies=2; I2=0%; very low CoE)]. Nonpharmacological treatments have been evaluated in RCTs/prospective comparative studies only sporadically. CONCLUSIONS: There is some evidence that usage of α1-blockers (alfuzosin and tamsulosin) may improve resolution of UR/BPO. As most nonpharmacological treatments have not been evaluated in patients with UR/BPO, the evidence is inconclusive about their benefits and harms. PATIENT SUMMARY: There is some evidence that alfuzosin and tamsulosin may increase the rates of successful trial without catheter, but little or no evidence on various nonpharmacological treatment options for managing patients with urinary retention secondary to benign prostatic obstruction.
引用
- Karavitakis M, Kyriazis I, Omar MI, et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol. 2019. PMID: 30773327. doi:10.1016/j.eururo.2019.01.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。